NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

Nektar Therapeutics (NKTR) shares rallied 38.2% last week, driven by growing investor optimism for its lead pipeline candidate, rezpegaldesleukin (rezpeg). This surge follows disappointing Phase III data for Sanofi's (SNY) competing atopic dermatitis drug, amlitelimab, which, despite meeting endpoints, was perceived by analysts as less effective than Dupixent. Investors are now speculating that Nektar's rezpeg, which previously showed positive Phase IIb results for atopic dermatitis and holds FDA Fast Track designation for both atopic dermatitis and alopecia areata, may have a stronger commercial future, despite being in an earlier development stage with Phase III trials anticipated in H1 2026 and long-term efficacy still to be determined.

Analysis

Nektar Therapeutics (NKTR) has experienced a significant stock price appreciation, rallying 38.2% in the past week and 188.1% year-to-date, driven by a positive shift in investor sentiment regarding its lead pipeline candidate, rezpegaldesleukin (rezpeg). The primary catalyst was not internal news, but rather disappointing Phase III trial data from competitor Sanofi for its atopic dermatitis candidate, amlitelimab. Although Sanofi's drug met its primary endpoints, investor and analyst perception was that its efficacy fell short of the market-leading incumbent, Dupixent, causing Sanofi's shares to decline. This has created a perceived market opportunity for Nektar's rezpeg, which boasts successful Phase IIb data for atopic dermatitis and operates via a different mechanism of action by selectively activating regulatory T-cells. Further bolstering the outlook, Nektar now has full, royalty-free ownership of rezpeg after regaining rights from Eli Lilly in April 2023, and the drug has received FDA Fast Track designation for both atopic dermatitis and alopecia areata. However, significant hurdles remain; rezpeg is still years from potential commercialization, with Phase III trials not expected to commence until the first half of 2026 and long-term efficacy yet to be proven.

Key Decisions for Investors

• Investors should recognize that the recent 38.2% rally in NKTR is speculative, based on a competitor's perceived weakness rather than new clinical data from Nektar, and the stock now prices in a higher probability of future success for rezpeg.
• Monitor key upcoming catalysts that will serve as major validation points, specifically the top-line data from the Phase IIb alopecia areata study expected in December 2025 and the successful initiation of Phase III trials in the first half of 2026.
• Given the stock's 188.1% year-to-date surge, existing holders may consider trimming positions to de-risk, while new investors should be cautious of the high valuation ahead of definitive late-stage clinical trial results and potential regulatory hurdles.